Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Share-based Compensation (2020 - 2025)

RxSight's Share-based Compensation history spans 6 years, with the latest figure at $7.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 7.35% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $31.6 million, up 142.7%, while the annual FY2025 figure was $31.6 million, 28.32% up from the prior year.
  • Share-based Compensation reached $7.8 million in Q4 2025 per RXST's latest filing, down from $8.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $8.5 million in Q2 2025 to a low of $222000.0 in Q3 2021.
  • Average Share-based Compensation over 5 years is $3.4 million, with a median of $2.8 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: crashed 64.54% in 2021, then skyrocketed 1609.4% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $2.9 million in 2021, then rose by 1.54% to $3.0 million in 2022, then soared by 49.39% to $4.4 million in 2023, then soared by 64.56% to $7.3 million in 2024, then rose by 7.35% to $7.8 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Share-based Compensation are $7.8 million (Q4 2025), $8.1 million (Q3 2025), and $8.5 million (Q2 2025).